This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Shares of Insmed (INSM) were among the best-performing health-related stocks Tuesday, climbing 17% after the company's drug Iplex received Food and Drug Administration approval.

The drug, which is used to treat growth failure in children who are missing a certain growth hormone, was granted orphan drug status, which means the company can market the drug on an exclusive basis for seven years. "We are very pleased Iplex was approved, making Iplex the only approved once-daily IGF-1 replacement therapy available to treat children with severe short stature," the company said.

Shares of Tercica (TRCA), which has a competing drug that's also been awarded orphan drug status, sank on Insmed's FDA approval news. Earlier this month, Tercica filed a lawsuit against Insmed, alleging that Insmed engaged in deceptive promotional statements and unfair business practices related to Tercica's competing Increlex product. Insmed said the complaint "is unwarranted and without merit." Shares of Insmed were recently trading up 26 cents to $1.75, while shares of Tercica tumbled $3.31, or 33%, to $6.59.

FoxHollow Technologies (FOXH) tumbled 15% after the medical device company announced the resignation of its chief executive officer. Robert Thomas, 44, will retire from the company on Jan. 1. John Simpson, founder and chairman, will serve as Thomas' replacement until the company names a new CEO. Thomas, who joined FoxHollow in 1998, will serve as a consultant to the company.

FoxHollow also said that it continues to expect fourth-quarter sales of $40 million to $42 million and full-year sales of $126 million to $128 million. Analysts polled by Thomson First Call project higher fourth-quarter sales of $43.4 million and 2005 sales of $129.4 million. Shares were trading down $7.11 to $39.01.

Shares of Vertex Pharmaceuticals (VRTX - Get Report) rose 3% after the company signed a new agreement with GlaxoSmithKline (GSK - Get Report) to develop and commercialize VX-409, a subtype selective sodium channel modulator that's used for pain treatment. GlaxoSmithKline will have the exclusive right to develop and commercialize VX-409. Vertex will receive an upfront payment of $20 million and could receive up to an additional $385 million if certain milestones are reached. GlaxoSmithKline will also pay Vertex royalties that are tied to annual sales. Vertex shares were trading up 75 cents to $27.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs